New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol
Lanskey J, Kocagoncu E, Quinn A, Cheng Y, Karadag M, Pitt J, Lowe S, Perkinton M, Raymont V, Singh K, Woolrich M, Nobre A, Henson R, Rowe J. New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol. BMJ Open 2022, 12: e055135. PMID: 36521898, PMCID: PMC9756184, DOI: 10.1136/bmjopen-2021-055135.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentEarly-stage Alzheimer's diseaseCognitive impairmentPeer-reviewed scientific journalsLongitudinal cohort studyResearch Ethics CommitteeAlzheimer's diseaseAmyloid-positive mild cognitive impairmentAlzheimer's disease studyConference presentationsCohort studyMeasures of diseaseCognitive AssessmentDisease StudyStudy protocolPrimary analysisEthics CommitteeLongitudinal changesParticipantsCognitive changesWebsite publicationClinical trial durationNew therapeuticsEast of England-Cambridge Central Research Ethics CommitteeProgression of Alzheimer's disease